Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1967 2
1968 2
1969 2
1970 22
1971 8
1972 6
1973 12
1974 18
1975 40
1976 50
1977 45
1978 72
1979 84
1980 104
1981 96
1982 94
1983 106
1984 85
1985 90
1986 73
1987 88
1988 85
1989 79
1990 66
1991 73
1992 68
1993 46
1994 42
1995 53
1996 29
1997 48
1998 40
1999 39
2000 38
2001 23
2002 22
2003 22
2004 19
2005 19
2006 15
2007 11
2008 14
2009 16
2010 14
2011 13
2012 21
2013 9
2014 6
2015 11
2016 8
2017 19
2018 18
2019 14
2020 9
2021 5
2022 16
2023 28
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

2,131 results

Results by year

Filters applied: . Clear all
Page 1
Disopyramide.
Koch-Weser J. Koch-Weser J. N Engl J Med. 1979 Apr 26;300(17):957-62. doi: 10.1056/NEJM197904263001705. N Engl J Med. 1979. PMID: 431563 No abstract available.
A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation.
Di Bianco R, Gottdiener JS, Singh SN, Fletcher RD. Di Bianco R, et al. Angiology. 1987 Feb;38(2 Pt 2):174-83. Angiology. 1987. PMID: 3103491 Review.
These primarily include the routine use of oral and especially intravenous loading dosages of disopyramide in an effort to attain rapid onset of action, the failure to adequately reduce dosages of disopyramide in the setting of compromised renal function, and, most …
These primarily include the routine use of oral and especially intravenous loading dosages of disopyramide in an effort to attain rap …
Disopyramide.
Morady F, Scheinman MM, Desai J. Morady F, et al. Ann Intern Med. 1982 Mar;96(3):337-43. doi: 10.7326/0003-4819-96-3-337. Ann Intern Med. 1982. PMID: 7036817 Review.
Since disopyramide was introduced 5 years ago, the therapeutic spectrum of this drug in treating patients with ventricular and atrial arrhythmias has been found to be similar to that of the other type I antiarrhythmic drugs, quinidine and procainamide. Disopyramide …
Since disopyramide was introduced 5 years ago, the therapeutic spectrum of this drug in treating patients with ventricular and atrial …
Disopyramide.
Vaughan Williams EM. Vaughan Williams EM. Ann N Y Acad Sci. 1984;432:189-200. doi: 10.1111/j.1749-6632.1984.tb14520.x. Ann N Y Acad Sci. 1984. PMID: 6395761 Review. No abstract available.
Clinical pharmacokinetics of disopyramide.
Siddoway LA, Woosley RL. Siddoway LA, et al. Clin Pharmacokinet. 1986 May-Jun;11(3):214-22. doi: 10.2165/00003088-198611030-00003. Clin Pharmacokinet. 1986. PMID: 3524956 Review.
Disopyramide is an antiarrhythmic agent with proven efficacy in the management of atrial and ventricular arrhythmias. ...Because the pharmacological effects of disopyramide are determined by unbound drug, changes in the unbound fraction could make total disopyram …
Disopyramide is an antiarrhythmic agent with proven efficacy in the management of atrial and ventricular arrhythmias. ...Because the …
Disopyramide--a review.
Ankier SI, Carmichael DJ, Kidner PH. Ankier SI, et al. Scott Med J. 1977 Oct;22(4):314-9. doi: 10.1177/003693307702200424. Scott Med J. 1977. PMID: 337485 Review. No abstract available.
Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Verlinden NJ, Coons JC. Verlinden NJ, et al. Pharmacotherapy. 2015 Dec;35(12):1164-72. doi: 10.1002/phar.1664. Pharmacotherapy. 2015. PMID: 26684556 Review.
The pharmacologic rationale for use of disopyramide is largely based on its strong negative inotropic property. Three clinical studies have showed significant improvements in heart failure symptoms and a reduction in the need for invasive therapy in patients treated with …
The pharmacologic rationale for use of disopyramide is largely based on its strong negative inotropic property. Three clinical studie …
Disopyramide-induced ventricular tachycardia.
Lo KS, Gantz KB, Stetson PL, Lucchesi BR, Pitt B. Lo KS, et al. Arch Intern Med. 1980 Mar;140(3):413-4. Arch Intern Med. 1980. PMID: 6153888
A patient with ischemic cardiomyopathy and congestive heart failure was treated with disopyramide phosphate for ventricular arrhythmias. The development of ventricular tachycardia was associated with elevated plasma disopyramide levels and prolongation of the …
A patient with ischemic cardiomyopathy and congestive heart failure was treated with disopyramide phosphate for ventricular ar …
Disopyramide.
Hayes JG. Hayes JG. Med J Aust. 1979 Jul 14;2(1):36. Med J Aust. 1979. PMID: 502945 No abstract available.
2,131 results